Finger P T
Department of Ophthalmology, New York Eye and Ear Infirmary, New York, USA.
Surv Ophthalmol. 1997 Nov-Dec;42(3):215-32. doi: 10.1016/s0039-6257(97)00088-x.
Radiotherapy offers patients with malignant melanoma of the choroid an eye and a vision-sparing alternative to enucleation. The most commonly used forms of radiotherapy are ophthalmic plaque brachytherapy and charged-particle (external beam) radiotherapy. Unfortunately, after all forms of radiotherapy for choroidal melanoma many patients experience sight-limiting side effects, and an average of 16.3% of patients treated with radiotherapy subsequently require enucleation because of tumor regrowth or uncontrollable neovascular glaucoma. The severity, location, and incidence of radiation-induced complications are related to the type of radiation used, its method of delivery, amount of radiation delivered to normal ocular structures, the size and location of the tumor, as well as its response to irradiation. Current research is directed toward developing methods to reduce the amount of radiation delivered to normal structures, e.g., adding heat to radiotherapy. The true viability and metastatic potential of irradiated uveal melanoma cells has not been established, although clinical studies have reported local control of choroidal melanoma in 81-100% (mean = 92.8%) of cases. The purpose of this review is to present the world's experience with radiotherapy for choroidal melanoma, information that will contribute to patient education and informed consent.
放射治疗为脉络膜恶性黑色素瘤患者提供了一种保留眼球和视力的替代眼球摘除术的方法。最常用的放射治疗形式是眼部敷贴近距离放射治疗和带电粒子(外照射)放射治疗。不幸的是,在对脉络膜黑色素瘤进行所有形式的放射治疗后,许多患者会出现限制视力的副作用,平均有16.3%接受放射治疗的患者随后因肿瘤复发或无法控制的新生血管性青光眼而需要进行眼球摘除术。辐射诱发并发症的严重程度、位置和发生率与所使用的辐射类型、其递送方法、传递到正常眼部结构的辐射量、肿瘤的大小和位置以及其对辐射的反应有关。目前的研究方向是开发减少传递到正常结构的辐射量的方法,例如在放射治疗中添加热量。尽管临床研究报告脉络膜黑色素瘤的局部控制率在81%-100%(平均=92.8%)的病例中,但照射后的葡萄膜黑色素瘤细胞的真正生存能力和转移潜力尚未确定。本综述的目的是介绍世界范围内脉络膜黑色素瘤放射治疗的经验,这些信息将有助于患者教育和知情同意。